Japan’s evolving regulatory environment is expanding how biotechs approach early development. With greater openness to global data, sponsors are increasingly evaluating where speed, predictability, and execution can best support long-term global goals.
Insights from BIO Japan highlight how sponsors are navigating these shifts through:
- Leveraging recent PMDA reforms to support global development planning
- Using Australia to accelerate early-phase and rare disease trials
- Generating clinical data that supports submissions in Japan, the US, and Europe
- Partnering with CROs that bring deep local and regional expertise